5 completed, 3 terminated, 2 recruiting, 1 active not recruiting. 5 Phase 2, 5 Phase 3, 3 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Terminated 2, Recruiting 1 |
| Phase 3 | 5 | Completed 3, Active not recruiting 1, Recruiting 1 |
| Phase 1 | 3 | Terminated 2, Completed 1 |
| Phase 4 | 1 | Not yet recruiting 1 |
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 4 Master Protocol for Patients Prescribed Prademagene Zamikeracel for the Treatment of Wounds Non-conforming pz-cel surgical application to RDEB wounds, Additional biopsies, Pz-cel surgical application to DEB wounds - Epidermolysis Bullosa (EB), Recessive Dystrophic Epidermolysis Bullosa (RDEB) | Phase 4 | Not yet recruiting | Abeona Therapeutics, Inc | 100 | 2026-11-01 | 2026-08-06 |
| A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting Prademagene Zamikeracel - Recessive Dystrophic Epidermolysis Bullosa | Recruiting | Abeona Therapeutics, Inc | 250 | 2025-07-25 | 2026-07-14 | |
| A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients EB-101 Surgical application of RDEB wounds - Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa | Phase 3 | Active not recruiting | Abeona Therapeutics, Inc | 12 | 2023-04-02 | 2025-06-27 |
| A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEB EB-101 - RDEB | Enrolling by invitation | Abeona Therapeutics, Inc | 22 | 2021-02-09 | 2026-07-17 | |
| A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101 ABO-101 - Mucopolysaccharidosis III-B | Terminated | Abeona Therapeutics, Inc | 1 | 2020-10-28 | 2022-05-31 | |
| Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) EB-101 - Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa | Phase 3 | Completed | Abeona Therapeutics, Inc | 11 | 2020-01-10 | 2022-12-05 |
| Gene Transfer Study of ABO-102 in Patients With Middle and Advanced Phases of MPS IIIA Disease ABO-102 - MPS IIIA, Sanfilippo Syndrome | Phase 1 / Phase 2 | Terminated | Ultragenyx Pharmaceutical Inc | 5 | 2019-09-18 | 2023-07-25 |
| Gene Transfer Clinical Trial for Mucopolysaccharidosis (MPS) IIIB rAAV9.CMV.hNAGLU - Mucopolysaccharidosis Type 3 B | Phase 1 / Phase 2 | Terminated | Abeona Therapeutics, Inc | 11 | 2017-10-16 | 2022-05-05 |
| Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH UX111, Prophylactic Immunomodulatory (IM) Therapy, Optimized Prophylactic IM Therapy - MPS IIIA, Sanfilippo Syndrome | Phase 2 / Phase 3 | Recruiting | Ultragenyx Pharmaceutical Inc | 36 | 2016-04-25 | 2026-09-22 |
| Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa LZRSE-Col7A1 Engineered Autologous Epidermal Sheets - Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa | Phase 1 / Phase 2 | Completed | Abeona Therapeutics, Inc | 12 | 2010-10-05 | 2023-08-22 |
| A Trial of the Safety and Efficacy of EcoNail™ in the Treatment of Fungus Infections of the Great Toenail EcoNail™ (econazole 5%/SEPA® 18% nail lacquer) - Onychomycosis | Phase 2 | Completed | Abeona Therapeutics, Inc | 40 | 2006-09-01 | 2020-09-03 |
| MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers ofloxacin, MSI-78 - Diabetic Foot Ulcers | Phase 3 | Completed | Abeona Therapeutics, Inc | 584 | 1994-08-01 | 2020-09-03 |
| MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers ofloxacin, MSI-78 - Diabetic Foot Ulcers | Phase 3 | Completed | Abeona Therapeutics, Inc | 342 | 1994-08-01 | 2020-09-03 |
Epidermolysis Bullosa Dystrophica (5) · Epidermolysis Bullosa (4) · Mucopolysaccharidosis III (4) · Diabetes Mellitus (2) · Diabetic Foot (2) · Ulcer (2) · Onychomycosis (1)
Ofloxacin (2) · pexiganan (2) · Econazole (1) · Separase (1) · Therapeutics (1)
United States (12) · Spain (3) · Australia (2) · France (2) · Germany (2)
Angela Iheanacho, MS (2) · Paul Litka, MD (2) · Sarah Abdelwahab, MD (2) · Jean Tang, MD (1) · Jean Tang, MD, PhD (1) · Michael H. Silverman, MD (1)
PMID 18990064, PMID 32884151, PMID 27802546, PMID 31578311, PMID 36253825, PMID 40570869
2015 (1), 2018 (1), 2019 (1), 2023 (1), R01AR055914 (1)